Long-acting growth hormone development

174:6

Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations

Jens Sandahl Christiansen^{1,*,†}, Philippe F Backeljauw², Martin Bidlingmaier^{3,*}, Beverly M K Biller^{4,*}, Margaret C S Boguszewski⁵, Felipe F Casanueva⁶, Philippe Chanson⁷, Pierre Chatelain⁸, Catherine S Choong⁹, David R Clemmons¹⁰, Laurie E Cohen¹¹, Pinchas Cohen^{12,*}, Jan Frystyk¹, Adda Grimberg¹³, Yukihiro Hasegawa¹⁴, Morey W Haymond¹⁵, Ken Ho¹⁶, Andrew R Hoffman^{17,*}, Jeff M P Holly¹⁸, Reiko Horikawa¹⁹, Charlotte Höybye²⁰, Jens Otto L Jorgensen¹, Gudmundur Johannsson²¹, Anders Juul²², Laurence Katznelson²³, John J Kopchick²⁴, K O Lee²⁵, Kuk-Wha Lee²⁶, Xiaoping Luo²⁷, Shlomo Melmed²⁸, Bradley S Miller²⁹, Madhusmita Misra⁴, Vera Popovic³⁰, Ron G Rosenfeld³¹, Judith Ross³², Richard J Ross³³, Paul Saenger³⁴, Christian J Strasburger^{35,*}, Michael O Thorner³⁶, Haim Werner³⁷ and Kevin Yuen³⁸

¹Aarhus University, Aarhus, Denmark, ²Cincinnati Children's Hospital, Cincinnati, Ohio, USA, ³Klinikum der Universität München, Munich, Germany, ⁴Massachusetts General Hospital, Boston, Massachusetts, USA, ⁵Federal University of Parana, Curitiba, Brazil, ⁶Santiago de Compostela University, Santiago de Compostela, Spain, ⁷Université Paris Saclay, Le Kremlin-Bicêtre, France, ⁸University Claude Bernard, Lyon, France, ⁹University of Western Australia, Subiaco, Western Australia, Australia, ¹⁰University of North Carolina, Chapel Hill, North Carolina, USA, ¹¹Boston Children's Hospital, Boston, Massachusetts, USA, ¹²University of Southern California, Los Angeles, California, USA, ¹³Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA, ¹⁴Tokyo Metropolitan Children's Medical Center, Tokyo, Japan, ¹⁵Baylor College of Medicine, Houston, Texas, USA, ¹⁶University of Queensland, Brisbane, Queensland, Australia, ¹⁷VA Palo Alto Health Care System and Stanford University, Palo Alto, California, USA, ¹⁸University of Bristol, Bristol, UK, ¹⁹National Center for Child Health and Development, Tokyo, Japan, ²⁰Karolinska University Hospital, Stockholm, Sweden, ²¹University of Gothenburg, Gothenburg, Sweden, ²²Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, ²³Stanford University, Stanford, California, USA, ²⁴Ohio University, Athens, Ohio, USA, ²⁵National University of Singapore, Singapore, Singapore, ²⁶UCLA School of Medicine, Los Angeles, California, USA, ²⁷Tongji Hospital, Wuhan, China, ²⁸Cedars-Sinai Medical Center, Los Angeles, California, USA, ²⁹Masonic Children's Hospital, Minneapolis, Minnesota, USA, ³⁰University of Belgrade, Belgrade, Serbia, ³¹ Stat5 Consulting, Los Altos, California, USA, ³²Jefferson Medical College, Philadelphia, Pennsylvania, USA, ³³University of Sheffield, Sheffield, UK, ³⁴SUNY, Stony Brook, New York, USA, ³⁵Charite-Universitätsmedizin, Berlin, Germany, ³⁶University of Virginia, Charlottesville, Virginia, USA, ³⁷Tel Aviv University, Tel Aviv, Israel, ³⁸Swedish Neuroscience Institute, Seattle, Washington, USA *(Member of the Planning Committee) [†](Deceased)

Correspondence should be addressed to A R Hoffman **Email** arhoffman@stanford.edu

Abstract

Objective: The Growth Hormone (GH) Research Society (GRS) convened a workshop to address important issues regarding trial design, efficacy, and safety of long-acting growth hormone preparations (LAGH). Participants: A closed meeting of 55 international scientists with expertise in GH, including pediatric and adult endocrinologists, basic scientists, regulatory scientists, and participants from the pharmaceutical industry. Evidence: Current literature was reviewed for gaps in knowledge. Expert opinion was used to suggest studies required to address potential safety and efficacy issues.

Consensus process: Following plenary presentations summarizing the literature, breakout groups discussed questions framed by the planning committee. Attendees reconvened after each breakout session to share group reports. A writing team compiled the breakout session reports into a draft document that was discussed and revised in an open forum on the concluding day. This was edited further and then circulated to attendees from academic



This work is licensed under a Creative Commons Attribution 3.0 Unported License institutions for review after the meeting. Participants from pharmaceutical companies did not participate in the planning, writing, or in the discussions and text revision on the final day of the workshop. Scientists from industry and regulatory agencies reviewed the manuscript to identify any factual errors.

Conclusions: LAGH compounds may represent an advance over daily GH injections because of increased convenience and differing phamacodynamic properties, providing the potential for improved adherence and outcomes. Better methods to assess adherence must be developed and validated. Long-term surveillance registries that include assessment of efficacy, cost-benefit, disease burden, quality of life, and safety are essential for understanding the impact of sustained exposure to LAGH preparations.

> *European Journal of Endocrinology* (2016) **174**, C1–C8

174:6

European Journal of Endocrinology

Background

The long-term safety and efficacy of daily recombinant human growth hormone (rhGH) have been well documented since its approval by the United States Food and Drug Administration (FDA) in 1985 and by the European Medicines Agency (EMA) in 1987. However, daily GH injections can be burdensome for some patients and caregivers. Furthermore, variability in clinical outcomes is well recognized in clinical practice, and may reflect differences in adherence to prescribed therapy (1). Published data and clinical experience indicate that nonadherence to daily rhGH therapy increases over time (2, 3, 4, 5, 6, 7, 8) and impairs therapeutic responses. Many life circumstances can interfere with adherence to daily injections, thus compromising therapeutic outcomes. By decreasing injection frequency, long-acting GH (LAGH) formulations may improve adherence and thereby potentially maximize clinical efficacy. Consequently, there are currently several LAGH preparations in various stages of preclinical development, with some already approved for clinical use (Table 1).

In light of the interest generated by these new formulations, the Growth Hormone Research Society (GRS) convened a workshop in Asilomar, CA, USA on 4–7 November 2015. The purpose of the workshop was to review the current state of the field and address key issues regarding trial design, efficacy, and safety of LAGH preparations.

Methods

Fifty-five invited international leaders from 14 countries across 5 continents with expertise in the field of GH attended the meeting. These included pediatric and adult endocrinologists, basic scientists, regulatory scientists from the FDA and EMA, and scientists from the pharmaceutical industry. A review of the current status of LAGH development was published before the meeting (9). A planning committee of the GRS comprising adult and pediatric endocrinologists from academic institutions determined the agenda, selected speakers to summarize key relevant topics, and formulated the questions for discussion at this workshop.

Following presentations that summarized the literature, four breakout groups addressed each topic in more detail by discussing the list of questions formulated by the planning committee and subsequently agreed upon by all participants. All attendees reconvened after each of the breakout sessions to share reports from the groups. At the end of days 1 and 2, a writing team compiled the breakout group reports into a final document that was reviewed and revised in its entirety by participants on the concluding day in an open forum. When there was no clear agreement by most participants, consensus was reached by voting. This draft document was edited further for formatting and references, and then recirculated to the academic attendees for final review after the meeting. Meeting participants from pharmaceutical companies were not part of the planning committee or writing team and were not present during the discussion and text revision on the final day. However, scientists from industry and regulatory agencies were shown the manuscript before submission in order to identify factual errors, but they were not involved in the writing. This report is a concise chronicle of the workshop and is not intended to be an exhaustive review of the literature on the topic. The contents of this manuscript were derived from: (i) the content of the speaker presentations, (ii) the combined comments of the breakout groups to the specific questions discussed, (iii) the collective remarks of the entire group during report-back sessions, and (iv) the current peer-reviewed literature in the GH field.

-
_
0
•
_
0
~
. =
· 🖂 👘
0
0
-
2
_
ш
÷
•
_
-
-
<u> </u>
<u> </u>
-
0
<u> </u>
1.1
_
5
w.
0
0
<u>د</u>
-
.

 Table 1
 Long-acting GH preparations.

Compary Compary Control Interaction on the GI molecule Depart interaction Control Interaction Depart form that in the GI molecule Mutricip in the GI molecule Id also Current status Depart form the market Depart intercontenting Id also Current status Current status Depart intercontenting Id also Current status Current status Current status Depart intercontenting Id also Current status Current status Current status Current status Current status Depart intercontenting Depart intercontenting FESystem Current status Current status Current status Current status Current status FESystem Current status Current status Current status Current status Current status FESystem Current status Current status Current status Current status Current status FESystem Current status Current status Current status Current status Current status FESystem Current status Current status Curent status <td< th=""><th></th><th></th><th></th><th></th><th></th><th></th></td<>						
Depot formulations Depot formulations Removed from the market beginstrate in biocompatible. Id days Removed from the market beginstrate in biocompatible. Removed from the market 16 Life Sciences, Ltd. LB300.2 Nutropin Depot Nutropin José Marketed in Socience Marketed in Socience 16 Life Sciences, Ltd. LB300.2 Nutropin José Adays Marketed in Socience Marketed in Socience 16 Life Sciences, Ltd. LB300.2 Nucropin José Adays Marketed in Socience Marketed in Socience 16 Life Sciences, Ltd. LB300.2 Nucropin José Adays Marketed in Socience Marketed in Socience Anthor, Adays Nucropin José Adays Marketed in Socience Marketed in Socience More Depot display Application Adays Nucropin José Adays No longer being developed indepoted in Adays More Depot display Application Marketed in Socience Adays No longer being developed indepoted in Adays No longer being developed indepoted in Adays Production More Depoted in Adays Adays No longer being developed indepoted in Adays No longer being developed indepoted in Adays		Company	Product	Modification to the GH molecule	Frequency of administration	Current status
Generated, building characterized, club sciences, Ltd. Nurropin Depot building characterized, powmer intersobiles, powmer intersobiles, p	Depot formulations			Depot chemical		
ICI Life Sciences, Ltd. LB302 Disolegradation polyacitide copyculation Tdays Marketer in Nores for instructionation Altus Pharmaceuticals ALTU-238 Disore or integnitien Tdays Marketer in Nores for instructionation FEGNated formulations Altus Pharmaceuticals ALTU-238 Disore or integnitien Tdays Marketer in Nores for instructionation FEGNated formulations Altus Pharmaceuticals ALTU-238 Disore in an UBase of integlin. Tdays Marketer in Nores for instructionationationationationationationationa		Genentech	Nutropin Depot	Encapsulated in biocompatible,	14 days	Removed from the market
Image: Interpret In				biodegradable, polylactide-coglycolide		
Contraction Control Contro Control Control Control <td></td> <td></td> <td></td> <td></td> <td>7 4000</td> <td>Markatia Karatar</td>					7 4000	Markatia Karatar
FEGylated formulations Anzult Controp arter intromotion and objects in the molynemic in the cope. Controp arter intromotion and objects in the molynemic in the cope. Control and objects in the molynemic in the cope. Control and objects in the molynemic in the cope. Control and objects in the molynemic in the cope. Control and objects in the cope. Copes the cope. Control and objects in the cope. Copes the cope. <thcope.< th=""> Copes the cope.</thcope.<>		רם דווב זרובוורבא' דוחי	LDJUUZ		/ uays	
After Febrations Contrastered in an on case or mecurum- critical Pharmaceuticals Contrastered contrast present in an on case or mecurum- critical Pharmaceuticals Contrastered contrast present in an on case or mecurum- critical Pharmaceuticals Contrastered contrast present in an on case or mecurum- critical Pharmaceuticals Contrastered contrast present present in an under critical Pharmaceuticals Contrastered contrast present critical Pharmaceuticals Contrastered contrast present present critical Pharmaceuticals Contrastered contrast present critical Pharmaceuticals Contrastered contrast present critical Pharmaceuticals Contrastered contrast present contrast present contra				Incorporated into sodium nyaluronate		cnilanooa GHU; Approvea
Hust Pharmaceuticals Critical Pharmaceuticals Current roystorides Total rowscoride rowscolid Total rowscolide Total rowscolide Total rowscolide Total rowscolides Total rowscoli rowscoli rowscolides Total rowscoli rowscolides<				and dispersed in an oil base of medium-		in Europe, but not marketed
Attu-238 Protein crystalization cachon dioxide, formed Zays No longer being developed FEGylated formulations ATV2-238 Protein crystalization cachon dioxide, formed 2 week planned) Preclinical studies ATVD ATV2-238 Protein cachon dioxide, formed 2 week planned) Preclinical studies ATVD ATV201 ATV201 3 cloba PEG added to unnatural amino 7 days No longer being developed Novo Nordisk AS NNC112.00033 43 cloba PEG residue attached to 7 days No longer being developed Production ATV201 3 cloba PEG added to unnatural amino 7 days No longer being developed Production ATV2013 ATV2013 3 cloba PEG residue attached to 7 days No longer being developed Production Tancon PEG cloba Tanscon PEG residue attached to 7 days No longer being developed Morecovalent albumin binding CH compound(s) Tanscon PEG residue attached to 7 days No longer being developed Non-covalent albumin binding CH compound(s) Tanscon PEG residue attached to 7 days No longer being developed Non-covalent albumin binding CH compound(s)<				chain triglycerides		in the EU.
Critical Pharmaceuticals CP016 Supercritical carbon dioxide, formed critical point, used to create the depot Ambrx Preclinical studies FEGVJated formulations Ambrx ARX201 Supercritical carbon dioxide, formed di monodia valo 7 days No longer being developed gluammer 41 Novo Nordisk AJS NNC1126-0083 3-0.4.02 FEG added to unnettural amino 3-0.4.02 FEG added to unnettural amino 7 days No longer being developed gluammer 41 Prizer Ereccinital Ereccinical studies 3-0.4.02 FEG added to unnettural amino 7 days No longer being developed gluammer 41 Prizer Ereccinital Ereccinical studies 3-0.4.02 FEG added to unnettural amino 7 days No longer being developed gluammer 41 Pro-drug formulations Transcon FEG diated 61 analog gluammer 41 7 days No longer being developed gluammer 41 Non-covalent albumin binding GH compound(s) Mechanism of conversion to attive 40 to gluam binding GH compound(s) 7 days Preclinical studies Non-covalent albumin binding GH compound(s) No longer being developed for non-covalent albumin binding GH compound(s) 7 days Preclinical studies Non-covalent albumin binding GH compound(s) Non-covalent albumin binding GH compound(s) 7 days Preclinical studies		Altus Pharmaceuticals	ALTU-238	Protein crystallization technology	7 days	No longer being developed
FG/ytated formulations ARX201 Avecades first hermodynamic registration true det coreate the depot Amb/x ARX201 ArX201 Avecades first hermodynamic registration FG/station 7 days No longer being developed acti incroptosted into GH No longer being developed developed Amb/x Novo Nordisk A/S NNC175-0083 3-kDa FEG residue attached to 3-kDa FEG residue attached to 7 days 7 days No longer being developed days (planned) Prodrug formulations Franscruticis Co. Ltd. Pharmaceuticis Co. Ltd. Phare 2 studies in children proceeries 7 days No longer being developed period oct DD Non-covalent albumin binding GH compound(s) Novo Nordisk A/S NuCO195-0092 Phare 2 studies in children proceeries Phare 2 studies in children proceeries Non-covalent albumin binding GH coreaceeries and Handok Rtd. Phare 2 studies in children proceeries Phare 2 studies in children proceeries Phare 2 studies in children proceeries Mateti Novo Nordisk A/S <t< td=""><td></td><td>Critical Pharmaceuticals</td><td>CP016</td><td>Supercritical carbon dioxide, formed</td><td>2 weeks planned)</td><td>Preclinical studies</td></t<>		Critical Pharmaceuticals	CP016	Supercritical carbon dioxide, formed	2 weeks planned)	Preclinical studies
FEGylated formulations Erticlal point, used to create the depot Ambrs Rex201 Rex201 Revision addimentation 7 days No longer being developed addimentation Novo Nordisk A/S NUC126-0083 3-4.0a FEG added to umatural amino addimentation 7 days No longer being developed genebicience Prizer Reinford Prizer Bolder No on ordisk A/S NUC126-0083 3-4.0a FEG added to umatural amino addimentation 7 days No longer being developed genebicience Prodrug formulations Prizer Ascendis TansCon PEG GH No longer being developed genebicience No longer being developed glutamine (AI No longer being developed glutamine (AI Nor-covalent albumin binding TansCon PEG GH Not transiently to a set/cleaving T days No longer being developed genebicience Nor-covalent albumin binding TansCon PEG GH No longer being developed genebicience T days No longer being developed genebicience Nor-covalent albumin binding T days T days T days T days T days Nor-covalent albumin binding T days T days T days T days T days T days Mor-covalent albumin binding T days				when CO ₂ exceeds its thermodynamic		
FGAylated formulations AR201 PEGylation 7 days No longer being developed Ambrs AR201 30-4ba FG added to unnatural amino 7 days No longer being developed Ambrs Novo Nordisk A/5 NNC175-0083 43-4ba FG residue attached to 7 days No longer being developed Pfizer Rescience Paramaceuticals Co., Ltd. Novo Nordisk A/5 No longer being developed Pharmaceuticals Co., Ltd. Mortology RES-GH PHA73428 Branched 40 kD FEG on N terminus of GH 7 days No longer being developed Pharmaceuticals Co., Ltd. Mortology RES-GH PHA73428 Resoned added to unnutural added to the transienty bound to GH 7 days No longer being developed Mortovalent albumin binding CH compound(s) Novo Nordisk A/5 Mortovalent albumin-binding 7 days Phase 2 studies in children Mortovalent albumin binding Novo Nordisk A/5 Mortovalent albumin-binding 7 days Phase 2 studies in children Mortovalent albumin-binding Movo Nordisk A/5 Mortovalent albumin-binding 7 days Phase 2 studies in children				critical point, used to create the depot		
Ambx ARX201 30-EDa FIG added to unnatural amino 7 days No longer being developed acid incorporated into GH 7 days No longer being developed glueamine 141 Novo Norcisk AJS NNC126-0083 30-EDa FIG residued at 0EG 7 days No longer being developed glueamine 141 Prizer Fizer Prizer No longer being developed glueamine 141 No longer being developed glueamine 141 No longer being developed glueamine 141 Prodrug formutations Birtolong Birtolong Birtolong Site-specific FEGylated GH analog 140-KD 7 days No longer being developed glueamine 141 Prodrug formutations Tanscon PEG GH Non-covalent albumin binding 7 days No longer being developed glueamine 141 Non-covalent albumin binding Tanscon PEG GH is unnotified. 7 days No longer being developed gluear activiter Non-covalent albumin binding Tanscon PEG GH is unnotified. 7 days Phase 2 studies in children gluear activiter Non-covalent albumin binding protein Novo Nordisk AS Nocondisk AS Novo Nordisk AS Non-covalent albumin binding protein Novo Nordisk AS Novo Nordisk AS Novo Nordisk AS GH fusion protein	PEGylated formulation	ions		PEGylation		
Novo Nordisk A/5 NNC1/26-0083 acid incorporated into GH 7 days No longer being developed glutamine 141 Pfaer Pfaer Pfaer NNC1/26-0083 3-8/40 PEG on Nerminus of GH 7 days No longer being developed glutamine 141 Pfaer Pfaer Pfaer 7 days No longer being developed glutamine 141 Redecience Pharmaceuticals Co., Ltd. Acborolis 7 days (planned) No longer being developed glutamine 141 Norocavalent albumin binding GH compound(s) TransCon PEG GH Nethanism of conversion to active drug (ACP-001) 7 days (planned) No longer being developed glutamine i a suff-cleaving Non-covalent albumin binding GH compound(s) TransCon PEG GH No longer being developed inheer. The released GH is unmodified. 7 days (planned) Pnase 2 studies in children fragins in children Non-covalent albumin binding GH compound(s) Ncol 95-0092 Single-print mustion in GH, with Novo Nordisk AS 7 days (planned) Pnase 2 studies in children Ref fusion proteins Ncol 95-0092 Single-print mustion in GH, with Novo Nordisk AS 7 days (planned) Pnase 2 studies in children GH fusion proteins Ncol 95-0092 Single-print mustion in GH, with Novo Nordisk AS <t< td=""><td></td><td>Ambrx</td><td>ARX201</td><td>30-kDa PEG added to unnatural amino</td><td>7 days</td><td>No longer being developed</td></t<>		Ambrx	ARX201	30-kDa PEG added to unnatural amino	7 days	No longer being developed
Novo Nordisk A5 NNC1126-0083 343-Da FEG residue attached to Dittamine 141 7 days No longer being developed developed Pfizer FEG-EH PHA-794428 Barnotadio 2 days (planned) No longer being developed Prizer FEG-EH PHA-794428 Barnotadio 2 days (planned) No longer being developed Prizer Personaceuticals Co. Ltd. No longer being developed 7 days (planned) No longer being developed Prodrug formulations TransCon PEG GH No conversion to active drug 7 days (planned) No longer being developed Non-covalent albumin binding GH compound(s) TransCon PEG GH No covalent albumin-binding 7 days (planned) Prase 2 studies in children Non-covalent albumin binding GH compound(s) No longer point mutation in GH, with Novo Nordisk AS No longer being developed Prase 2 studies in children Novo Nordisk AS No longer point mutation in GH, with Novo Nordisk AS Prober GH Albumin binding Prase 2 studies in children Novo Nordisk AS Novo Nordisk AS No Corporative devint GH Prase 2 studies in children Prase 2 studies in children GH fusion proteins GH fusion for non-cycloylic To days				acid incorporated into GH	s.	-)
Pfizer Bolder BioTechnology BeT-331 EG-GH PHA-79428 Butamine (41) Butamine (41) Butamine (41) Display (4) (4)-KDa FEG ant Mermius of GH and 9G (4)-KDa FEG artached to GH Pharmaceuticals Co. Ltd. No Inoger being developed (4)-KDa FEG artached to GH (4)-KDa FEG artached to GH (4)-KDA		Novo Nordisk A/S	NNCI126-0083	43-kDa PEG residue attached to	7 days	No longer being developed
Pfize Brids Pfize Brids T days (adys (planned) T days preclinical studies geneSidence geneSidence preclinical studies (advs (planned) Pfize preclinical studies preclinical studies preclinical studies (advs (planned) Prize preclinical studies preclinical studies preclinical studies Prodrug formulations Prodrug formulations Prodrug formulations Ascendis Prize preclinical studies preclinical studies Prize preclinical studies preclinical studies Preclinical studies preclinical studies Pro-drug formulations Ascendis TransCon PEG GH (ACP-001) Methanism of conversion to active drug prescription 7 days Phase 2 studies in children and adults Non-covalent albumin binding GH compound(s) Noc Nordisk AS Noc Nordisk AS Noc Nordisk AS Phase 2 studies in children and adults Mon-covalent albumin binding mole profention fusion Non-covalent albumin-binding properties) 7 days Phase 2 studies in children and phase 3 studies in children properties) GH tusion proteins Asterion Genexine and Handok RocPuse GH Grupolization on on-cycloptic 7 days Preclinical studies in adults Asterion Genexine and Handok GCX-H9 Monodimetical gycosylated IgG4 FC 7-14 days Prase 2 studies in children properties) Asterion Genexine and Handok MOD-4023 Monodimetical gycosylated IgG4 FC 7-				glutamine 141		
Bolder BioTechnology BBT-031 BBT-031 Directore Site-specific FG/ylated GH analog 7 days 7 days preclinical studies Preclinical studies Pro-drug formulations TransCon FEG GH TransCon FEG GH AckDa FEG artached to GH 7 days Pharetedin Linina for fulthood GHD Pharetedin Linina for fulthood GHD Pro-drug formulations TransCon FEG GH Non-towersion to active drug 7 days Phase 2 studies in children fulthood GHD Non-covalent albumin binding GH compound(s) TransCon FEG GH NC0195-0092 Sile-point functionin 7 days Phase 2 studies in children and adutts Non-covalent albumin binding Novo Nordisk ArS NC0195-0092 Sile-point functionin 7 days Phase 2 studies in children and adutts GH fusion protein Acteoin Retain the intrationin binding on concalent albumin-binding 7 days Phase 2 studies in children and Phase 3 studies in children (non-covalent albumin-binding GH fusion protein Genexine and Handok RX-H9 Protein fused with GH 7 days Phase 2 studies in children and Phase 2 studies in children (non-covalent albumin-binding GH fusion protein Genexine and Handok RX-H9 Protein fused with GH 7 days Phase 2 studies in children (non-covalent albumin-binding GPK Hami		Pfizer	PEG-GH PHA-794428	Branched 40 kD PEG on N terminus of GH	7 davs	No longer being developed
Pharmaceuticals Co., Ltd. Introlong 40-Kba PEG attached to GH 7 days Marketed in China for childhood GHD Pro-drug formulations TransCon PEG GH Mechanism of conversion to active drug 7 days Marketed in China for childhood GHD Pro-drug formulations TransCon PEG GH Mechanism of conversion to active drug 7 days Phase 2 studies in children Mon-covalent albumin binding GH compound(s) NNC0195-0092 Mabumin binding inter The released GH is ummodified. 7 days Phase 2 studies in children Mon-covalent albumin binding for concousient binding on concretish Totals 7 days Phase 2 studies in children Mon-covalent albumin binding for concretish Profession in GH, with asterion 7 days Phase 2 studies in children Mon-covalent albumin binding for concretish Profession in GH, with and aduts 7 days Phase 2 studies in adults GH fusion proteins Profession of non-cytolytic for monty of tgD One month (planned) Profession adults Asterion Profession of non-cytolytic minunoglobulin Fc portions of tgD One month (planned) Prase 2 studies in adults Monti Fragment Mon-drog adition of non-cytolytic Total days Prase 2 studies in adults Monti Fragment Total days Total days Prase 2 studies in adults Monti Fragment Total days Fragment		Bolder BioTechnology	BBT-031	Site-specific PEGvlated GH analog	7 davs (planned)	Preclinical studies
Pro-drug formulations Ascendis Transcon PEG GH (ACP-001) Mechanisention of conversion to active drug GH fransiently bunding (ACP-001) Interstendisently bunding interst. The released GH is unmodified. childhood GHD mechanisently bunding and adults Non-covalent albumin binding GH compound(s) Novo Nordisk AS Norol95-0092 Norol95-0092 Norol95-0092 Norol95-0092 Norocovalent albumin binding inding 7 days Phase 2 studies in children and adults Norocovalent albumin binding Novo Nordisk AS Norol95-0092 Single-point mutation in GH, with albumin binding oncor-covalent albumin-binding 7 days Phase 2 studies in children and Phase 3 studies in children and Phase 3 studies in children (non-covalent albumin-binding GH fusion proteins Asterion Profiles GH Provelut flag 7 days Phase 3 studies in children and Phase 3 studies in adults GH fusion proteins Genexine and Handok ProFiles GH Provelut flag 7 days Phase 2 studies in children and IGG4 Hanni Pharmaceutical Co. LAPSrhGH/HM 10560A Homodimeric aglycosylated IGG4 FC 7-14 days Phase 2 studies in children and IGG4 Favor ProFiles Albumineric aglycosylated IGG4 FC 7-14 days Phase 2 studies in children and IGG4 Phase 3 studies in children and Phase 3 studies in children and Phase 3 studies in child		GeneScience	Jintrolona	40-kDa PEG attached to GH	7 davs	Marketed in China for
Prodrug formulationsTansCon PEG GHMechanism of conversion to active drug (ACP-001)TansCon PEG GHMechanism of conversion to active drug (ACP-001)Tanscon PEG GHTanscon FEG HTanscon FEG HTansco		Pharmaceuticals Co., Ltd.)		'n	childhood GHD
Ascendis TransCon PEG GH (ACP-001) GH transiently bound to a (ACP-001) TansCon PEG GH (ACP-001) GH transiently bound to a inker. The released GH is unmodified. Phase 2 studies in children and adutts Non-covalent albumin binding Novo Nordisk AS NnC0195-0092 Albumin binding inker. The released GH is unmodified. Phase 2 studies in children and adutts Albumin binding Novo Nordisk AS NnC0195-0092 Single-point mutation in GH, with and phase 3 studies in children (non-covalent albumin-binding properties) 7 days Phase 2 studies in children and Phase 3 studies in children properties) GH fusion proteins Genexine and Handok Protein fused with GH (non-covalent albumin-binding properties) 7 days Phase 2 studies in children and Phase 3 studies in adutts Hanni Pharmaceutical Co. LAPSrhGH/HM10560A Hybridization of non-cytolytic (mmunoglobulin Fc portions of IgD and IgG4 7 days Phase 2 studies in adutts Tava Phase 2 studies in adutts 7 days Phase 2 studies in adutts Mamin Pharmaceutical Co. LAPSrhGH/HM10560A Hybridization of IgG4 7 -14 days Phase 2 studies in adutts Fava NCD Health and Pizer MOD-4023 Phase 3 studies in children (NCTO) of NCS 7 days Phase 2 studies in children (NCTO) of NCS Fava	Pro-drug formulatio	SU		Mechanism of conversion to active drug		
Ascends Transcon red off is unmodified. Transe of red off is unmodified. Non-covalent albumin binding GH compound(s) ACP-001) Transe of the released GH is unmodified. Albumin binding Non-covalent albumin binding motex NNC0195-0092 Single-point mutation in GH, with and abumin binding motex attached for and bumin binding motex attached for and bumin binding motex Albumin binding motex Advise in dufts GH fusion proteins Asterion Profuse GH RH binding protein 7 days Prase 2 studies in children and bumin binding motex GH fusion proteins Asterion Profuse GH Prove with GH One month (planned) Prase 2 studies in children and lats Genexine and Handok GX-H9 Phinding protein One month (planned) Preclinical studies Genexine and Handok GX-H9 Hanni Pharmaceutical Co. LAPSrhGH/HM10560A Hondimeric aglycos/stacd IgG4 Fc 7-14 days Phase 2 studies in children More of IgG Hanni Pharmaceutical Co. LAPSrhGH/HM10560A Hondimeric aglycos/stacd IgG4 Fc 7-14 days Phase 2 studies in children Teva Prase 3 rudies in children Prese 2 rudies in children Prese 2 rudies in children Prase 2 rudies in childre						محمدا والمعاقمة معالم بشور محمطوا
Act-U01) Ped carrier molecule via a seth-cleaving linker. The released GH is unmodified. And aduits Non-covalent albumin binding Novo Nordisk A/S NNC0195-0092 Single-point mutation in GH, with albumin binding 7 days Phase 2 studies in children and Phase 3 studies in children (non-covalent albumin-binding properties) Phase 2 studies in children albumin-binding GH fusion proteins Asterion Profein fused with GH 7 days Phase 3 studies in children and Phase 3 studies in aduits GH fusion proteins Asterion Profein fused with GH 7 days Prase 2 studies in aduits Asterion Profein fused with GH One month (planned) Prase 2 studies in aduits Asterion Profein fused with GH One month (planned) Phase 2 studies in aduits Asterion Profein fused with GH One month (planned) Phase 2 studies in aduits Asterion Profein of non-cytolytic immunoglobulin Fc portions of IgD 7-14 days Phase 2 studies in children Anomi Pharmaceutical Co. LAPSrhGH/HM 10560A Hondimeric aglycosylated IgG4 Fc 7-14 days Phase 2 studies in children Teva Phase 2 studies in aduits Phase 2 studies in aduits Phase 2 studies in children Teva Phase Phase Phase		Ascenais			/ days	Phase 2 studies in children
Non-covalent albumin binding Novo Nordisk AS Nucor195-0092 Nucor195-0092 Albumin binding former. The released GH is unmodrited. Novo Nordisk AS Nucor195-0092 Single-point mutation in GH, with albumin binding moiety attached (non-covalent albumin-binding form-covalent albumin-binding form-covalent albumin-binding 7 days Phase 2 studies in children and Phase 3 studies in dults GH fusion proteins Genexine and Handok ProFuse GH GX-H9 Profuse dwith GH Profici attached (non-covalent albumin-binding protein Genexine and Handok ProFuse GH GH binding protein Genexine and Handok Profuse GH GH binding protein Harmi Pharmaceutical Co. LAPSrhGH/HM10560A Non-cyclytic Harmi Pharmaceutical Co. Profuse GH Harmi Pharmaceutical Co. LAPSrhGH/HM10560A Profuse GH GH cortions of IgD and IgG4 Prase 2 studies in adults Teva TV-106 Harmin Pharmaceutical Co. LAPSrhGH/HM10560A Homodimeric aglycosylated IgG4 Fc 7-14 days Phase 2 studies in adults Teva TV-105 Harmi Pharmaceutical Co. LAPSrhGH/HM10560A Homodimeric aglycosylated IgG4 Fc 7-14 days Phase 2 studies in children and IgG4 Teva Teva TV-105 Harmin Pharmaceutical Co. LAPSrhGH/HM10560A Phase 2 studies in adults Teva Teva Total days Total days			(ACP-001)	PEG carrier molecule via a self-cleaving		and adults
Non-covalent albumin binding GH compound(s) Albumin binding Single-point mutation in GH, with albumin binding moiety attached (non-covalent albumin-binding properties) Adbumin binding albumin binding (non-covalent albumin-binding properties) Pase 2 studies in children and Phase 3 studies in dults GH fusion proteins Asterion Genexine and Handok ProFuse GH (Ar+9) Protein fused with GH (non-covalent albumin-binding properties) 7 days Prase 3 studies in children and Phase 3 studies in adults Hanni Pharmaceutical Co. LAPSrhGH/HM10560A Hybridization of non-cytolytic immunoglobulin Fc portions of IgD One month (planned) Practinical studies Phase 2 studies in adults Manni Pharmaceutical Co. LAPSrhGH/HM10560A Homodimeric aglycosylated IgG4 Fc 7-14 days Phase 2 studies in adults More Mandok Graboxyl-terminal peptide (CTP) of hCG 7 days Phase 2 studies in children and IgG4 More Mare Mare Mare Mare Mare Mare Mare Ma		:		linker. The released GH is unmodified.		
Novo Nordisk A/S NNC0195-0092 Single-point mutation in GH, with and burnin binding moiety attached albumin binding moiety attached (non-covalent albumin-binding properties) 7 days Phase 2 studies in children and Phase 3 studies in dults GH fusion proteins Asterion ProFuse GH Profein fused with GH One month (planned) Preclinical studies in adults GH fusion proteins Profein fused with GH One month (planned) Preclinical studies in adults Asterion Profein fused with GH One month (planned) Preclinical studies in adults Asterion Genexine and Handok GX-H9 Hybridization of non-cyclolytic 7-14 days Phase 2 studies in adults Hanmi Pharmaceutical Co. LAPSrhGH/HM10560A Homodimeric aglycosylated IgG4 Fc 7-14 days Phase 2 studies in adults OPKO Health and Pfizer MOD-4023 Carboxyl-terminal peptide (CTP) of hCG 7 days Phase 3 studies in children Teva Teva Totals have been discontinued 7 days Phase 3 studies in children Versartis VR5-317 XTEN sequence: naturally occurring 7-14 days Phase 3 studies in adults Feva NS-317 XTEN sequence: naturally occurring 7 days 7 days Fradies in children	Non-covalent albun	nin binding GH compound(s)		Albumin binding		
GH fusion proteins) albumin binding moiety attached (non-covalent albumin-binding protenties) and Phase 3 studies in dults (non-covalent albumin-binding protenties) GH fusion proteins ProFuse GH ProFuse GH ProFuse GH ProFuse GH ProFuse GH Asterion ProFuse GH GH binding protein ProFuse GH ProFuse GH ProFuse GH Asterion Genexine and Handok ProFuse GH GH binding protein One month (planned) Preclinical studies in adults Hanmi Pharmaceutical Co. LAPSrhGH/HM10560A Homodimeric aglycosylated IgG4 FC 7-14 days Phase 2 studies in adults OPKO Health and Pfizer MOD-4023 Homodimeric aglycosylated IgG4 FC 7-14 days Phase 2 studies in adults Teva MOD-4023 Carboxyl-terminal peptide (CTP) of hCG 7 days Phase 3 studies in adults Teva TV-1106 TV-1106 Albumin 7 days Phase 3 studies in children Versartis TreVa VRS-317 XTEN sequence: naturally occurring 7 days Phase 3 studies in children Morophilic amino acids T-14 days Phase 3 studies in adults 7 days Phase 3 studies in adults		Novo Nordisk A/S	NNC0195-0092	Single-point mutation in GH, with	7 days	Phase 2 studies in children
GH fusion proteins (non-covalent albumin-binding protein strong properties) (non-covalent albumin-binding protein strong properties) Protein trsed with GH Protein trsed with GH Protein trsed with GH Protein strong properties) Preclinical studies Asterion Prof-us Prof-us Protein trsed with GH One month (planned) Preclinical studies Asterion Ranmi Pharmacutical Co. LAPSrhGH/HM10560A Hybridization of non-cytolytic D-14 days Phase 2 studies in adults Alanmi Pharmaceutical Co. LAPSrhGH/HM10560A Homodimeric aglycosylated IgG4 Fc 7-14 days Phase 2 studies in adults OPKO Health and Pfizer MOD-4023 Carboxyl-terminal peptide (CTP) of hCG 7 days Phase 2 studies in adults Teva To-1106 Abumin 7 days Phase 3 studies in adults Versartis TV-1106 Abumin 7 days Phase 3 studies in adults Versartis TV-1105 Abumin 7 days Phase 3 studies in adults Versartis To-1105 Albumin 7 days Phase 3 studies in adults Versartis To-14 days Phase 3 studies in adults Phase 3 studies in adults Feva To-14 days <td< td=""><td></td><td></td><td></td><td>albumin binding moiety attached</td><td>,</td><td>and Phase 3 studies in dults</td></td<>				albumin binding moiety attached	,	and Phase 3 studies in dults
GH fusion protein Asterion ProFuse GH Properties) Asterion ProFuse GH ProFuse with GH Asterion ProFuse GH Phase GH Asterion Genexine and Handok GX-H9 Hybridization of non-cytolytic 7-14 days Preclinical studies Hanmi Pharmaceutical Co. LAPSrhGH/HM10560A Homodimeric aglycosylated IgG4 Fc 7-14 days Phase 2 studies in adults OPKO Health and Pfizer MOD-4023 Homodimeric aglycosylated IgG4 Fc 7-14 days Phase 2 studies in adults Teva TV-1106 Homodimeric aglycosylated IgG4 Fc 7-14 days Phase 2 studies in adults Teva NCO-4023 Earboxyl-terminal peptide (CTP) of hCG 7 days Phase 2 studies in adults Teva TV-1106 P-14 days 7 days Phase 2 studies in adults Versartis TV-1106 Albumin 7 days Phase 3 studies in adults Versartis VRS-317 XTEN sequence: naturally occurring 7-14 days Phase 3 studies in adults Proforphilic amino acids Total adv 7 days Phase 2 studies in adults Phase 3 studies in adults				(non-covalent albumin-binding		
GH fusion proteins Profein fused with GH One month (planned) Preclinical studies Asterion ProFuse GH Hybridization of non-cytolytic One month (planned) Preclinical studies Asterion Genexine and Handok GX-H9 Hybridization of non-cytolytic 7–14 days Preclinical studies Hanmi Pharmaceutical Co. LAPSrhGH/HM10560A Homodimeric aglycosylated lgG4 Fc 7–14 days Phase 2 studies in adults OPKO Health and Pfizer MOD-4023 Homodimeric aglycosylated lgG4 Fc 7–14 days Phase 2 studies in adults Teva Teva To-4023 Homodimeric aglycosylated lgG4 Fc 7–14 days Phase 2 studies in adults Teva MOD-4023 Carboxyl-terminal peptide (CTP) of hCG 7 days Phase 2 studies in children Teva Teva Teva To-4 days Phase 3 studies in adults Versartis To-1106 Haumin 7 days Phase 3 studies in adults Versartis VRS-317 NRS-317 Tadys Phase 3 studies in children Versartis VRS-317 NRS-317 To ads Phase 3 studies in children Mydrophilic To-4 days To ads Pha				properties)		
AsterionProFuse GHGH binding proteinOne month (planned)Preclinical studiesGenexine and HandokGX-H9Hybridization of non-cytolytic7–14 daysPhase 2 studies in adultsGenexine and Harmaceutical Co.LAPSrhGH/HM10560AHomodimeric aglycosylated IgG4 Fc7–14 daysPhase 2 studies in adultsHanmi Pharmaceutical Co.LAPSrhGH/HM10560AHomodimeric aglycosylated IgG4 Fc7–14 daysPhase 2 studies in adultsOPKO Health and PfizerMOD-4023Homodimeric aglycosylated IgG4 Fc7–14 daysPhase 2 studies in adultsTeagmentTeragment7 daysPhase 2 studies in adultsand lgfanTevaTV-1106P-subunit7 daysTrials have been discontinuedVersartisVRS-317XTEN sequence: naturally occurring7-14 daysand Phase 2 studies in adultsManninTevaTV-11067 daysPhase 2 studies in adultsTevaTV-11067 days7 daysPhase 3 studies in childrenVersartisVRS-317XTEN sequence: naturally occurring7-14 daysPhase 2 studies in adultsHanninPhase 2 studies in adultsPhase 2 studies in adultsPhase 2 studies in adults	GH fusion proteins			Protein fused with GH		
Genexine and HandokGX-H9Hybridization of non-cytolytic7–14 daysPhase 2 studies in adultsImmunoglobulin FC portions of IgDand IgG47–14 daysPhase 2 studies in adultsHanmi Pharmaceutical Co.LAPSrhGH/HM10560AHomodimeric aglycosylated IgG4 FC7–14 daysPhase 2 studies in adultsCPKO Health and PfizerMOD-4023Fragment7–14 daysPhase 2 studies in childrenTevaTV-1106Pase 2 studies in adults7 daysPhase 3 studies in adultsTevaTV-1106Albumin7 days7 daysTrials have been discontinuedVersartisVRS-317XTEN sequence: naturally occurring7–14 days7 adies in childrenVersartisTotal7 daysPhase 3 studies in adults7 daysPase 2 studies in adults7 daysPhase 2 studies in childrenVersartisVRS-317XTEN sequence: naturally occurring7–14 days7 adies in childrenPase 2 studies in adults7 daysPhase 2 studies in adults7-14 days7 adies in children		Asterion	ProFuse GH	GH binding protein	One month (planned)	Preclinical studies
Immunoglobulin Fc portions of IgD Immunoglobulin Fc portions of IgD Hanmi Pharmaceutical Co. LAPSrhGH/HM10560A Homodimeric aglycosylated IgG4 Fc 7–14 days Phase 2 in adults OPKO Health and Pfizer MOD-4023 Carboxyl-terminal peptide (CTP) of hCG 7 days Phase 2 studies in children Teva TV-1106 P-subunit 7 days Trials have been discontinued Versartis VRS-317 XTEN sequence: naturally occurring 7-14 days Phase 2 studies in children Modification 7 days 7 days 7 days 7 days 7 days Versartis VRS-317 XTEN sequence: naturally occurring 7-14 days 7 days 7 days		Genexine and Handok	GX-H9	Hybridization of non-cytolytic	7–14 days	Phase 2 studies in adults
and IgG4Hanmi Pharmaceutical Co.LAPSrhGH/HM10560AHomodimeric aglycosylated IgG4 Fc7–14 daysPhase 2 in adultsCPKO Health and PfizerMOD-4023Carboxyl-terminal peptide (CTP) of hCG7 daysPhase 2 studies in childrenTevaTV-1106PhaseAlbunit7 daysTrials have been discontinuedVersartisVRS-317XTEN sequence: naturally occurring7-14 daysPhase 2 studies in childrenModificaninaPhaseAlbunin7 daysTrials have been discontinuedVersartisVRS-317XTEN sequence: naturally occurring7-14 daysPhase 2 studies in childrenPhasePhaseStudies in childrenPhaseStudies in childrenPaseVRS-317VRS-317PhasePhaseStudies in childrenPasePhasePhaseStudies in childrenPhaseStudies in childrenPasePhasePhaseStudies in adultsPhaseStudies in adultsPasePhasePhasePhaseStudies in adultsPasePhasePhasePhasePhasePhasePasePhasePhasePhasePhasePhasePasePhasePhasePhasePhasePhasePasePhasePhasePhasePhasePhasePasePhasePhasePhasePhasePhasePasePhasePhasePhasePhasePhasePasePhasePhasePhasePhasePhase <t< td=""><td></td><td></td><td></td><td>immunoglobulin Fc portions of IgD</td><td></td><td></td></t<>				immunoglobulin Fc portions of IgD		
Hanmi Pharmaceutical Co. LAPSrhGH/HM10560A Homodimeric aglycosylated lgG4 Fc 7–14 days Phase 2 in adults Fragment fragment fragment Fragment Phase 2 studies in children OPKO Health and Pfizer MOD-4023 Carboxyl-terminal peptide (CTP) of hCG 7 days Phase 2 studies in children Teva p-subunit 7 days Trials have been discontinued Versartis VRS-317 XTEN sequence: naturally occurring 7–14 days Phase 2 studies in children Versartis VRS-317 hydrophilic amino acids 7–14 days mad Phase 2 studies in adults				and lgG4		
Tragment Tragment OPKO Health and Pfizer MOD-4023 Carboxyl-terminal peptide (CTP) of hCG 7 days Phase 2 studies in children Pase 2 studies in adults P-subunit 7 days Phase 3 studies in adults Teva TV-1106 Albumin 7 days Trials have been discontinued Versartis VRS-317 XTEN sequence: naturally occurring 7-14 days Phase 2 studies in adults hydrophilic amino acids 7-14 days and Phase 2 studies in adults		Hanmi Pharmaceutical Co.	LAPSrhGH/HM 10560A	Homodimeric aglycosylated IgG4 Fc	7–14 days	Phase 2 in adults
OPKO Health and Pfizer MOD-4023 Carboxyl-terminal peptide (CTP) of hCG 7 days Phase 2 studies in children Phase 2 studies in children p-subunit p-subunit and Phase 3 studies in adults Teva Tv-1106 Albumin 7 days Trials have been discontinued Versartis VRS-317 XTEN sequence: naturally occurring 7–14 days Phase 2 studies in children hydrophilic amino acids naturally occurring 7–14 days Phase 2 studies in children				fragment		
β-subunit β-subunit and Phase 3 studies in adults Teva TV-1106 Albumin 7 days Trials have been discontinued Versartis VR5-317 XTEN sequence: naturally occurring 7-14 days Phase 3 studies in children hydrophilic amino acids hydrophilic amino acids and Phase 2 studies in adults		OPKO Health and Pfizer	MOD-4023	Carboxyl-terminal peptide (CTP) of hCG	7 days	Phase 2 studies in children
Teva TV-1106 Albumin 7 days Trials have been discontinued Versartis VR5-317 XTEN sequence: naturally occurring 7–14 days Phase 3 studies in children hydrophilic amino acids hydrophilic amino acids and Phase 2 studies in adults				β-subunit		and Phase 3 studies in adults
Versartis VRS-317 XTEN sequence: naturally occurring 7–14 days Phase 3 studies in children hydrophilic amino acids and Phase 2 studies in adults		Teva	TV-1106	Albumin	7 days	Trials have been discontinued
hydrophilic amino acids and Phase 2 studies in adults		Versartis	VRS-317	XTEN sequence: naturally occurring	7–14 days	Phase 3 studies in children
				hydrophilic amino acids		and Phase 2 studies in adults

www.eje-online.org

Long-acting growth hormone development

C3

174:6

C4

174:6

The clinical need for a LAGH preparation in pediatric and adult endocrinology

Large interindividual variability in the growth response to daily GH injections in GH-deficient children and adults reflects numerous inherent biological factors, including dosing and dose frequency and varying sensitivity to both exogenous GH and endogenous insulin-like growth factor 1 (IGF1) (10, 11). In addition, reduced adherence to daily injections likely compromises response to treatment. The requirement for daily injections may also represent a barrier to initiating and maintaining therapy in both pediatric and adult patients. Many scenarios were discussed in which LAGH would represent a significant innovation in the delivery of clinical care for patients deficient in GH. All participants recognized the need for LAGH.

Development of LAGH preparations

As described in the review prepared for this workshop (9), several technologies are being used to prolong GH exposure. These include: (i) depot formulations, (ii) pegylation, (iii) prodrugs, (iv) noncovalent albumin binding GH compound(s), and (v) GH-fusion proteins (Table 1). These preparations are currently in various stages of development, with some already approved in Europe and Asia.

Endocrine features of LAGH

There was overall consensus that currently available data do not allow determination of whether the effects of LAGH will differ from those of daily GH. In addition, it is not clear whether the physiological GH pulsatility and diurnal secretory pattern seen in normal subjects are important for attaining optimal injected GH effects (12). It has been emphasized that many currently prescribed hormone replacement therapies, including daily GH, glucocorticoids, and various formulations of sex steroids, do not replicate normal physiologic pattern of secretion of the endogenous hormones in terms of pulsatility and diurnal variation. The LAGH preparations that were used in clinical trials, as well as continuous infusions of GH, did not result in tachyphylaxis or substantial differences in clinical effects when compared with daily injections of GH (13, 14, 15, 16).

Safety considerations unique to LAGH

LAGH products exhibit different pharmacokinetics and pharmacodynamics compared with daily GH and,

therefore, safety considerations may be specific to these formulations. In particular, the mechanism whereby each product prolongs the action of GH differs; such additional moieties or properties may have an impact on safety distinct from considerations about GH or IGF1 levels. Therefore, the safety of each individual LAGH product should be assessed. Also, there is a need to consider the pharmacodynamic impact of each LAGH product. Care should be taken to avoid overtreatment, and therefore safety monitoring is critically important. Potential issues include: (i) supraphysiological elevations of GH and/or IGF1, (ii) trough GH concentrations above normal physiological levels, (iii) fluctuating IGF1 levels, (iv) elevated IGF1 in the absence of GH bioactivity, (v) nonphysiological tissue distribution due to distinct biological features of the products, and (vi) the specific chemical composition of each LAGH product may confer unique safety issues.

The impact on safety of longer exposure to GH and/or IGF1 with the LAGH preparations is unclear. Serum IGF1 levels are generally higher immediately following an injection and lower before the next injection. It will be important to associate IGF1 levels with side effects.

In children and adolescents, rare side effects of daily GH replacement include intracranial hypertension, slipped capital femoral epiphyses, and hyperglycemia in those at risk for diabetes (17). Whether LAGH will exacerbate these risks is unknown. The safety issues need to take into account specific factors including age, pubertal stage, and populations at risk for diabetes (particularly certain GH therapeutic indications such as small for gestational age (SGA) and Turner syndrome). In patients who develop the rare and serious side effect of benign intracranial hypertension, daily GH therapy is suspended until the condition resolves. One theoretical (and important) concern with LAGH is that the long duration of action does not allow immediate reversibility of exogenous GH exposure. In young children with congenital, severe GH deficiency, hypoglycemia may occur when the drug effect wanes. In such patients, prospective studies would need to include monitoring blood glucose levels at the end of the LAGH dosing interval, when serum GH levels may be at their lowest.

In children and adults, it is unclear whether carbohydrate or lipid metabolism (18) will differ between LAGH and daily GH-treated patients. Glucose metabolism should be monitored in patients on LAGH because of concerns related to the possibility of prolonged GH bioactivity (19).

C5

174:6

The theoretical concerns regarding whether there is an effect of GH treatment on neoplasia were addressed in recently published position papers (20, 21, 22). These concerns may also apply to LAGH. The impact of possible supraphysiological and sustained GH and IGF1 levels after an injection and the altered balance between GH and IGF1 with LAGH on potential long-term cancer risk is unknown. Childhood cancer survivors should be monitored for possible development of secondary neoplasms, especially those who received cranial irradiation.

Daily administration of GH results in a consistent day-to-day hormonal and metabolic response (23). In contrast, LAGH administration may result in different patterns on each day within the dosing interval, and the long-term consequences of this pattern are unknown. It is important to emphasize that neither daily GH nor LAGH products recapitulate normal physiologic secretion.

LAGH preparations may result in injection site pain, skin irritation, allergic reactions, and lipoatrophy (24). These effects, which were reported in some early LAGH studies, vary among preparations (25). The incidence of local skin reactions for each preparation should be explored further.

IGF1 measurements during LAGH administration

Unlike the experience with daily GH, both the appropriate timing of blood sampling and the interpretation of the IGF1 standard deviation score (SDS) in LAGH-treated patients are controversial. LAGH preparations differ in the kinetics of serum GH and IGF1 that they induce. Studies need to take into account the pharmacokinetics and pharmacodynamics of each product in order to gauge the optimal timing of IGF1 measurement. The goal is to maintain serum IGF1 concentrations within the normal age-appropriate range for a majority of the treatment period.

The role of antibody measurements

Antibody measurements are used to assess potential immunogenicity that may impact both efficacy and safety. Because the impact of these antibodies on clinical outcomes is unclear, the interpretation of such results and the assimilation into study design need to be considered. Specifically, it is clinically important to determine whether there are neutralizing antibodies that could inhibit the intended drug effects. Discontinuation of LAGH in the face of rising antibody titers may be considered if there is a clinically significant reduction in IGF1 response or growth velocity or coexistence of a severe allergic reaction. However, there are challenges in interpreting these results due to the marked variability of antibody assays.

Pediatric trial design

The goals of pediatric GH therapy are to maximize adult height and to bring children into the normal height range as soon as possible. Primary outcomes include first year height velocity and delta height SDS (26); however, the most practical endpoint to measure in a Phase 3 pediatric clinical trial is height velocity. In addition, secondary outcomes include height velocity SDS, delta height velocity, bone age advancement, predicted adult height, and delta IGF1 SDS. Nongrowth outcomes should also be measured, including body composition, metabolic indices, and percentage of children entering puberty. Additional patient-related outcomes to be monitored include adherence, quality of life (QoL), and patient satisfaction. Models to assess burden of disease and therapy should be developed.

A trial duration of 1 year in prepubertal, treatmentnaïve children was considered appropriate to assess efficacy using a carefully matched control group. Longer treatment duration is required to assess the safety profiles of the LAGH preparations. Weightbased fixed dosing was advised for pediatric Phase 3 trials, with downward dose titration performed for elevated serum IGF1 levels demonstrated on at least two consecutive measurements. It is important to establish the appropriate time between injections for IGF1 measurement. Opinions differ on the utility of peak, mean, and trough IGF1 concentrations as tools to monitor and guide therapy. Phase 2 results for each product should provide information to determine which IGF1 measurement time point is clinically useful.

It is important to ensure matched study populations when comparing LAGH with daily GH. Variables to consider should include age, gender, midparental target height, onset of puberty, ethnicity, severity of growth hormone deficiency (GHD), and BMI-SDS. It will be essential to define selective benefits and risks of LAGH in randomized controlled trials in pediatric populations other than GHD, such as Turner syndrome, chronic renal failure, Prader–Willi syndrome, Noonan syndrome, short children born SGA, and idiopathic short stature. It should not be assumed that the effects and safety profile of LAGH in these other conditions will be similar to those seen with LAGH therapy in GHD.

via free access

174:6

In clinical trials, safety monitoring should be performed after 1 and 3 months, and then every 3 months thereafter. This should include assessment of glucose regulation with hemoglobin A1c, fasting glucose, and insulin levels. Hepatic, thyroid, and adrenal function should also be monitored. However, in formal surveillance programs and clinical practice, these safety parameters should be considered annually.

Adult trial design

Daily GH replacement therapy for adult GHD was approved by the United States FDA in 1996, using changes in body composition as the primary outcome. Additional outcome measures that could be evaluated in LAGH trials include patient-recorded outcomes such as QoL, exercise capacity, and work productivity. A trial duration of 6 months is considered appropriate to assess efficacy. As in the pediatric trials, it is important to include carefully matched control groups. Attention should also be paid to the many variables previously described including age, gender, severity of GHD, and BMI when comparing LAGH with daily GH therapy. Safety of LAGH in adults can only be determined after a long treatment duration, and therefore extension studies may be required after completion of the controlled trials.

Truncal or visceral fat reduction at 6 months is recommended as the primary end point in adult trials. Secondary end points (some of which would require longer treatment duration) include IGF1, QoL, lipid profiles, exercise capacity, cardiovascular risk factors, and bone mineral density. The initial dose should take into account age, gender, and oral estrogen use in women. Study design in adults should include a dose titration to achieve a mean serum IGF1 in the normal age-appropriate range, with the timing of the IGF1 measurement based on pharmacodynamic findings for each compound.

Safety monitoring with laboratory tests, similar to those described above for the pediatric trials, should be performed at 1, 3, and 6 months on treatment and then at regular intervals (sooner if clinically indicated) in clinical trial extensions, formal surveillance programs, and in clinical practice. Brain MRI should be performed before the start of LAGH and as clinically indicated thereafter in patients with GHD due to hypothalamic–pituitary tumors.

Adherence

Adherence to therapy is an extremely important variable that is difficult to assess reliably. Clinical trials select

for motivated participants and the infrastructure of these studies enhance adherence. Methods to monitor adherence include vial count, electronic devices, webbased entry, and patient diaries. Serum IGF1 may be a surrogate marker of compliance. Measurement of LAGH by product-specific assays may be useful. Adherence may also be affected by ease of use of the delivery device, but little data are available to assess this supposition (27, 28).

Conclusion

LAGH compounds are a novel approach to the therapy of GHD and other growth disorders. LAGH may represent an advance over daily GH injections because of the potential for improved adherence and outcomes. LAGH may offer patients and families therapeutic alternatives and flexibility. Better methods to assess adherence need to be developed and validated. Long-term surveillance registries that include assessment of long-term efficacy, cost-effectiveness, disease burden, QoL, and safety measures are essential for understanding the impact of chronic exposure to all preparations of LAGH.

Declaration of interest

J S C: consultant for Ascendis Pharma A/S, Novo Nordisk, and Teva. P F B: consulted for Ipsen, Novo Nordisk, EMD Serono, Versartis, and Sandoz, and currently receives grant support from Versartis. M B: consults for Genexine. OKPO, Sandoz, Teva, and Versartis, and has previously consulted for Biopartners. B M K B: PI, research grants to Massachusetts General Hospital from OPKO Biologics, Novo Nordisk, Versartis. Consultant to: Novo Nordisk, Pfizer, and Versartis. M C S B: consulted for Pfizer; lecture fees from Pfizer, Merck Serono. F F C: research grants, lecture, or consulting fees from Pfizer. PhC: research and educational grants from Ipsen, Novo Nordisk, and has served as investigator for clinical trials funded by Pfizer, Ipsen, Prolor Biotech. Member of Advisory Boards from Ipsen, Eli Lilly. Gave lectures for Ipsen and Pfizer. All the fees and honoraria were paid to his institution. PierreC: consulted for, principal investigator of a clinical trial, and speaker or chair in meetings promoted by Merck Serono and Ascendis Pharma A/S. C S C: research support from Merck Serono. D R C: consulted for Pfizer and Novo Nordisk. L E C: honorarium from Scherer Clinical Communications. PinchasC: consults for Ascendis Pharma A/S, OPKO Biologics, Teva, and Versartis. J F: nothing to disclose. A G: consults for the Pfizer International Growth Study database. Y H: nothing to disclose. M W H: nothing to disclose. K H: receives lecture fees from Ipsen and consults for Versartis and Pfizer. A R H: consults for Teva, Ascendis Pharma A/S, Versartis, and Genexine. J H: nothing to disclose. R H: nothing to disclose. CH: investigator for Novo Nordisk, Teva, Ascendis Pharma A/S, Versatis, and Handok-Genexine and has consulted for Novo Nordisk and Teva. J O L J: lecture fees and grant support from Pfizer and Novo Nordisk. G J: lecture fees from Novo Nordisk, Pfizer, and Merck Serono and has received grant support (2010-2015) from Novo Nordisk, Pfizer, and Sandoz. A J: lecture fees from Ipsen, Novo Nordisk, Ferring, and Sandoz; principal investigator on a multicenter trial, which received unrestricted grant support from Novo Nordisk. L K: nothing to disclose. J J K: consults for Teva and EMD Serono; lecture fees from Pfizer; inventor of Growth Hormone Antagonists (US Patent # 5,350,836). K O L: nothing to disclose. K W L: nothing to disclose. X L: consults for Gensci, Ipsen, Merck Serono, Novo Nordisk.

174:6

S M: research grant support from Versartis. B S M: consults for Alexion, BioMarin, Endo Pharmaceuticals, Genentech, Ipsen, Novo Nordisk, Sandoz, and Versartis and has received research support from Alexion, Abbvie, Eli Lilly, Debiopharm, Endo Pharmaceuticals, Genentech, Ipsen, Novo Nordisk, Pfizer, Sandoz, and Versartis. M M: consulted for Genentech. V P: PI in clinical research studies for LG Life Science, OPKO Biologics, Versartis, Hanmi, and Teva. R G R: consults for Ascendis Pharma A/S, OPKO Biologics, Versartis, Teva, Genexine, Novo Nordisk, and Sandoz. J R: research support from Eli Lilly, Novo Nordisk, and Versartis and consults for and serves on an advisory board for Novo Nordisk. R J R: equity interests in Diurnal Ltd and Asterion Ltd. P S: consults for Ascendis Pharma A/S, Teva, OPKO Biologics. Speaker bureau Novo Nordisk, C J S: consults for Prolor, Versartis, Novo Nordisk, Merck Serono, Pfizer, and Genexine. M O T: Founder and CSO Ammonett Pharma, which is developing a ghrelin mimetic. H W: nothing to disclose. K Y: research grant support from Pfizer, Novo Nordisk, Eli Lilly, OPKO Biologics, Teva, and Versartis, and has served on the advisory boards for Pfizer, Novo Nordisk, Sandoz, and Versartis.

Funding

This work was supported by the Growth Hormone Research Society.

Acknowledgment

The GRS and all the authors of this report would like to thank the following individuals for their participation in the workshop and their invaluable comments and perspectives:

Regulatory scientists:

United States FDA: Smita Abraham, Jean-Marc Guettier, and Marina Zemskova; EMA: Thorsten Vetter

Industry observers:

Michael Beckert (Ascendis Pharma A/S), George Bright (Versartis), Jose Cara (Pfizer), Susan K Durham (Immunodiagnostic Systems), Gili Hart (OPKO Biologics), Michael Højby (Novo Nordisk), Lein Jin (GeneSci), Udo Mueller (Teva), Markus Zabransky (Sandoz), and Tony Mason (Ferring).

Dedication

The authors dedicate this paper to our late colleague and friend, Jens Sandahl Christiansen, a consummate clinical investigator and a kind and devoted physician.

References

- 1 Bang P, Bjerknes R, Dahlgren J, Dunkel L, Gustafsson J, Juul A, Kriström B, Tapanainen P & Aberg V. A comparison of different definitions of growth response in short prepubertal children treated with growth hormone. *Hormone Research Paediatrics* 2011 **75** 335–345. (doi:10.1159/000322878)
- 2 Holdaway IM, Hunt P, Manning P, Cutfield W, Gamble G, Ninow N, Staples-Moon D, Moodie P & Metcalfe S. Three-year experience with access to nationally funded growth hormone (GH) replacement for GH-deficient adults. *Clinical Endocrinology* 2015 83 85–90. (doi:10.1111/cen.2015.83.issue-1)
- 3 Bang P, Ahmed SF, Argente J, Backeljauw P, Bettendorf M, Bona G, Coutant R, Rosenfeld RG, Walenkamp MJ & Savage MO. Identification and management of poor response to growthpromoting therapy in children with short stature. *Clinical Endocrinology* 2012 **77** 169–181. (doi:10.1111/cen.2012.77.issue-2)
- 4 Haverkamp F, Johansson L, Dumas H, Langham S, Tauber M, Veimo D & Chiarelli F. Observations of nonadherence to recombinant human growth hormone therapy in clinical practice. *Clinical Therapeutics* 2008 **30** 307–316. (doi:10.1016/ j.clinthera.2008.02.017)

- 5 Cutfield WS, Derraik JG, Gunn AJ, Reid K, Delany T, Robinson E & Hofman PL. Non-compliance with growth hormone treatment in children is common and impairs linear growth. *PLoS ONE* 2011 **6** e16223. (doi:10.1371/journal.pone.0016223)
- 6 Kapoor RR, Burke SA, Sparrow SE, Hughes IA, Dunger DB, Ong KK & Acerini CL. Monitoring of concordance in growth hormone therapy. *Archives of Diseases in Children* 2008 **93** 147–148. (doi:10.1136/ adc.2006.114249)
- 7 Rosenfeld RG & Bakker B. Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. *Endocrine Practice* 2008 14 143–154. (doi:10.4158/EP.14.2.143)
- 8 Lass N & Reinehr T. Low treatment adherence in pubertal children treated with thyroxin or growth hormone. *Hormone Research Paediatrics* 2015 84 240–247. (doi:10.1159/000437305)
- 9 Høybye C, Cohen P, Hoffman AR, Ross R, Biller BM, Christiansen JS & Growth Hormone Research Society. Status of long-acting-growth hormone preparations – 2015. *Growth Hormone and IGF Research* 2015 25 201–206. (doi:10.1016/j.ghir.2015.07.004)
- 10 Ranke MB & Lindberg A. Predicting growth in response to growth hormone treatment. *Growth Hormone and IGF Research* 2009 **19** 1–11. (doi:10.1016/j.ghir.2008.08.001)
- 11 Johannsson G, Bjarnason R, Bramnert M, Carlsson LM, Degerblad M, Manhem P, Rośen T, Thorén M & Bengtsson BA. The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH binding protein, body mass index, age and gender. *Journal of Clinical Endocrinology and Metabolism* 1996 **81** 1575–1581. (doi:10.1210/jc.81.4.1575)
- 12 Laursen T, Jørgensen JO, Jakobsen G, Hansen BL & Christiansen JS. Continuous infusion versus daily injections of growth hormone (GH) for 4 weeks in GH-deficient patients. *Journal of Clinical Endocrinology and Metabolism* 1995 **80** 2410–2418. (doi:10.1210/jcem.80.8.7543114)
- 13 Laursen T, Gravholt CH, Heickendorff L, Drustrup J, Kappelgaard AM, Jørgensen JO & Christiansen JS. Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults. *Journal of Clinical Endocrinology and Metabolism* 2001 **86** 1222–1228. (doi:10.1210/jcem.86.3.7323)
- 14 Hoffman AR, Biller BM, Cook D, Baptista J, Silverman BL, Dao L, Attie KM, Fielder P, Maneatis T, Lippe B & Genentech Adult Growth Hormone Deficiency Study Group. Efficacy of a long-acting growth hormone (GH) preparation in patients with adult GH deficiency. *Journal of Clinical Endocrinology and Metabolism* 2005 **90** 6431–6440. (doi:10.1210/jc.2005-0928)
- 15 Khadilkar V, Raduk K, Bolshova E, Khadgawat R, El Kholy M, Desai M, Peterkova V, Mericq V, Kratzsch J, Christine Siepl E *et al.* 24-month use of once weekly GH, LB03002 in prepubertal children with GH deficiency. *Journal of Clinical Endocrinology and Metabolism* 2014 **99** 126–132. (doi:10.1210/jc.2013-2502)
- 16 Hou L, Chen ZH, Chen YG & Luo XP. Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children. *Drug Design, Development and Therapy* 2016 **10** 13–21.
- 17 Clayton PE & Cowell CT. Safety issues in children and adolescents during growth hormone therapy – a review. *Growth Hormone and IGF Research* 2000 **10** 306–317. (doi:10.1054/ghir.2000.0175)
- 18 Oscarsson J, Ottosson M, Johansson J-O, Wiklund O, Mårin P, Björntorp P & Bengtsson BA. Two weeks of daily injections and continuous infusion of recombinant human growth hormone (GH) in GH-deficient adults: II. Effects on serum lipoproteins and lipoprotein and hepatic lipase activity. *Metabolism* 1996 **45** 370–377. (doi:10.1016/S0026-0495(96)90293-0)
- 19 Krusenstjerna-Hafstrøm T, Clasen BF, Møller N, Jessen N, Pedersen SB, Christiansen JS & Jørgensen JO. Growth hormone (GH)-induced insulin resistance is rapidly reversible: an experimental study in

www.eje-online.org

GH-deficient adults. *Journal of Clinical Endocrinology and Metabolism* 2011 **96** 2548–2557.

- 20 Allen DB, Backeljauw P, Bidlingmaier M, Biller B, Boguszewski M, Burman P, Butler G, Chihara K, Christiansen JS, Cianfarani S *et al.* Growth hormone safety workshop position paper: a critical appraisal of recombinant human growth hormone therapy in children and adults. *European Journal of Endocrinology* 2016 **174** P1–P9. (doi:10.1530/EJE-15-0533)
- 21 Raman S, Grimberg A, Waguespack SG, Miller BS, Sklar CA, Meacham LR & Patterson BC. Risk of neoplasia in pediatric patients receiving growth hormone therapy – a report from the Pediatric Endocrine Society Drug and Therapeutics Committee. *Journal of Clinical Endocrinology and Metabolism* 2015 **100** 2192–2203. (doi:10.1210/jc.2015-1002)
- 22 Patterson BC, Chen Y, Sklar CA, Neglia J, Yasui Y, Mertens A, Armstrong GT, Meadows A, Stovall M, Robison LL *et al.* Growth hormone exposure as a risk factor for the development of subsequent neoplasms of the central nervous system: a report from the childhood cancer survivor study. *Journal of Clinical Endocrinology and Metabolism* 2014 **99** 2030–2037. (doi:10.1210/jc.2013-4159)
- 23 Jørgensen JO, Møller N, Lauritzen T, Alberti KG, Orskov H & Christiansen JS. Evening versus morning injections of growth hormone (GH) in GH-deficient patients: effects on 24-hour patterns of circulating hormones and metabolites. *Journal of Clinical Endocrinology and Metabolism* 1990 **70** 207–214. (doi:10.1210/ jcem-70-1-207)
- 24 Touraine P, D'Souza GA, Kourides I, Abs R, Barclay P, Xie R, Pico A, Torres-Vela E, Ekman B & GH Lipoatrophy Study Group. Lipoatrophy

in GH deficient patients treated with a long-acting pegylated GH. *European Journal of Endocrinology* 2009 **161** 533–540. (doi:10.1530/EJE-09-0422)

174:6

- 25 Biller BM, Ji HJ, Ahn H, Savoy C, Siepl EC, Popovic V, Coculescu M, Roemmler J, Gavrila C, Cook DM *et al.* Effects of once-weekly sustained-release growth hormone: a double-blind, placebo-controlled study in adult growth hormone deficiency. *Journal of Clinical Endocrinology and Metabolism* 2011 **96** 1718–1726. (doi:10.1210/ jc.2010-2819)
- 26 Cohen P, Rogol AD, Deal CL, Saenger P, Reiter EO, Ross JL, Chernausek SD, Savage MO & Wit JM on behalf of the 2007 ISS consensus workshop participants. Consensus guidelines for the diagnosis and treatment of children with idiopathic short stature: a summary statement of the Growth Hormone Research Society, The Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. *Journal of Clinical Endocrinology and Metabolism* 2008 **93** 4210–4217. (doi:10.1210/ jc.2008-0509)
- 27 Fuchs GS, Mikkelsen S, Knudsen TK & Kappelgaard AM. Ease of use and acceptability of a new pen device for the administration of growth hormone therapy in pediatric patients: an open-label, uncontrolled usability test. *Clinical Therapeutics* 2009 **31** 2906–2914. (doi:10.1016/j.clinthera.2009.12.014)
- 28 Meinhardt U, Eiholzer U, Seitz L, Bøgelund M & Kappelgaard AM. Parent preference in Switzerland for easy-to-use attributes of growth hormone injection devices quantified by willingness to pay. *Expert Review of Medical Devices* 2014 **11** 31–38. (doi:10.1586/17434440.2014.856754)

Received 6 February 2016 Revised version received 16 March 2016 Accepted 23 March 2016